Experimental immune cell therapy targets tough leukemia

NCT ID NCT05712278

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-phase study tested an off-the-shelf natural killer (NK) cell therapy called SAR445419 in adults with acute myeloid leukemia that returned or didn't respond to treatment. Participants received chemotherapy followed by the NK cells to see if it was safe and could help control the disease. The study was terminated early after enrolling only 7 people.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloblastic leukemia with maturation acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Albert Einstein College of Medicine Site Number : 8400001

    The Bronx, New York, 10461, United States

  • University of Nebraska Medical Center Site Number : 8400003

    Omaha, Nebraska, 68198-2168, United States

  • ~MD Anderson Cancer Center Site Number : 8400002

    Houston, Texas, 77030, United States